Emerging treatments for advanced pancreatic cancer: clinical potential of albumin-bound paclitaxel

References

• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–1403.
   PubMed Web of Science ®Google Scholar
• Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2013. Ann Oncol. 2013;24:792–800.
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal D. Cancer Statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
   PubMed Web of Science ®Google Scholar
• Willett CG, Czito BJ, Bendell JC, Ryan DP. Locally advanced pancreatic cancer. J Clin Oncol. 2005;23:4538–4544.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073–1081.
   PubMed Web of Science ®Google Scholar
• Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–1481.
   PubMed Web of Science ®Google Scholar
• Tempero MA, Berlin J, Ducreux M, et al. Pancreatic cancer treatment and research: an international expert panel discussion. Ann Oncol. 2011;22:1500–1506.
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413.
   PubMed Web of Science ®Google Scholar
• Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, Phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25:2212–2217.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513–5518.
   PubMed Web of Science ®Google Scholar
• Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group directed Intergroup Trial S0205. J Clin Oncol. 2010;28:3605–3610.
   PubMed Web of Science ®Google Scholar
• Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28:3617–3622.
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–1966.
   PubMed Web of Science ®Google Scholar
• Poplin E, Feng Y, Rothenberg ML, et al. Phase III trial of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:3778–3785.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–1825.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;31:369:1691–1703.
   Google Scholar
• Heinemann V, Reni M, Ychou M, Richel DJ, Macarulla T, Ducreux M. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Cancer Treat Rev. 2014;40:118–128.
   PubMed Web of Science ®Google Scholar
• Erkan M, Hausmann S, Michalski CW, et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol. 2012;9:454–467.
   PubMed Web of Science ®Google Scholar
• Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605–1617.
   PubMed Web of Science ®Google Scholar
• Kleeff J, Beckhove P, Esposito I, et al. Pancreatic cancer microenvironment. Int J Cancer. 2007;121:699–705.
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2007;6:1186–1197.
   PubMed Web of Science ®Google Scholar
• Bachem MG, Schunemann M, Ramadani M, et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology. 2005;128:907–921.
   PubMed Web of Science ®Google Scholar
• Apte MV, Park S, Phillips PA, et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas. 2004;29:179–187.
   PubMed Web of Science ®Google Scholar
• Farrow B, Sugiyama Y, Chen A, Uffort E, Nealon W, Mark Evers B. Inflammatory mechanisms contributing to pancreatic cancer development. Ann Surg. 2004;239:763–769.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Kleeff J, Kayed H, et al. Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells. Mol Carcinog. 2002;35:138–147.
   PubMed Web of Science ®Google Scholar
• Erkan M, Adler G, Apte MV, et al. Current consensus and discussion on pancreatic stellate cell research. Gut. 2012;61:172–178.
   PubMed Web of Science ®Google Scholar
• Erkan M, Reiser-Erkan C, Michalski CW, et al. The impact of the activated stroma on pancreatic ductal adenocarcinoma biology and therapy resistance. Curr Mol Med. 2012;12:288–303.
   PubMed Web of Science ®Google Scholar
• Ohlund D, Franklin O, Lundberg E, Lundin C, Sund M. Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop. BMC Cancer. 2013;13:154.
   PubMed Web of Science ®Google Scholar
• Shields MA, Dangi-Garimella S, Krantz SB, Bentrem DJ, Munshi HG. Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion. J Biol Chem. 2011;286:10495–10504.
   PubMed Web of Science ®Google Scholar
• Miyamoto H, Murakami T, Tsuchida K, Sugino H, Miyake H, Tashiro S. Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas. 2004;28:38–44.
   PubMed Web of Science ®Google Scholar
• Fujita H, Ohuchida K, Mizumoto K, et al. Tumor-stromal interactions with direct cell contacts enhance proliferation of human pancreatic carcinoma cells. Cancer Sci. 2009;100:2309–2317.
   Web of Science ®Google Scholar
• Erkan M, Reiser-Erkan C, Michalski CW, Kleeff J. Tumor microenvironment and progression of pancreatic cancer. Exp Oncol. 2010;32:128–131.
   Google Scholar
• Schneiderhan W, Diaz F, Fundel M, et al. Pancreatic stellate cells are an important source of MMP-2 in human pancreatic cancer and accelerate tumor progression in a murine xenograft model and CAM assay. J Cell Sci. 2007;120:512–519.
   PubMed Web of Science ®Google Scholar
• Xu Z, Vonlaufen A, Phillips PA, et al. Role of pancreatic stellate cells in pancreatic cancer metastasis. Am J Pathol. 2010;177:2585–2596.
   PubMed Web of Science ®Google Scholar
• Erkan M, Michalski CW, Rieder S, et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 2008;6:1155–1161.
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Maitra A. The hedgehog pathway and pancreatic cancer. N Engl J Med. 2009;361:2094–2096.
   PubMed Web of Science ®Google Scholar
• Di Marco M, Macchini M, Vecchiarelli S, Sina S, Biasco G. Hedgehog signaling: from the cuirass to the heart of pancreatic cancer. Pancreatology. 2012;12:388–393.
   Web of Science ®Google Scholar
• Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457–1461.
   PubMed Web of Science ®Google Scholar
• Jimeno A, Feldmann G, Suarez-Gauthier A, et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther. 2009;8:310–314.
   PubMed Web of Science ®Google Scholar
• Khan GN, Griffith K, Greenson J, et al. Cancer stem cells (CSC) and inhibition of hedgehog (Hh) pathway signaling in advanced pancreatic cancer: GDC-0449 in combination with gemcitabine (Gem). Abstract presented at the American Association for Cancer Research’s Pancreatic Cancer: Progress and Challenges conference, Lake Tahoe, Nevada, USA, June 18–21, 2012.
   Google Scholar
• Richards DA, Stephenson J, Wolpin BM, et al. A Phase Ib trial of IPI-926 a hedgehog pathway inhibitor plus gemcitabine in patients with metastatic pancreatic cancer. J Clin Oncol. 2012;30 Suppl 4:Abstr 213.
   Google Scholar
• Infinity Pharmaceuticals. Infinity reports update from Phase 2 study of saridegib plus gemcitabine in patients with metastatic pancreatic cancer. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=121941&p=irol-newsArticle&ID=1653550&highlight. Accessed January 02, 2014.
   Google Scholar
• Virgil D, Catenacci T, Bahary N, et al. Final analysis of a Phase IB/randomized Phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): a University of Chicago Phase II consortium study. J Clin Oncol. 2013;31 Suppl:Abstr 4012.
   Google Scholar
• ClinicalTrials.Gov. Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas Available from http://clinicaltrials.gov/ct2/show/NCT01088815. ClinicalTrials.gov Identifier: NCT01088815. Accessed March 21, 2014.
   Google Scholar
• ClinicalTrials.Gov. FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma Available from http://clinicaltrials.gov/ct2/show/NCT01383538. ClinicalTrials.gov Identifier: NCT01383538. Accessed March 21, 2014.
   Google Scholar
• ClinicalTrials.Gov. LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer Available from http://clinicaltrials.gov/ct2/show/NCT01485744. ClinicalTrials.gov Identifier: NCT01485744. Accessed March 21, 2014.
   Google Scholar
• Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:418–429.
   PubMed Web of Science ®Google Scholar
• Borad MJ, Ramanathan RK, Bessudo A, et al. Targeting hyaluronan (HA) in tumor stroma: a Phase I study to evaluate the safety pharmacokinetics (PK) and pharmacodynamics (PD) of pegylated hyaluronidase (PEGPH20) in patients with solid tumors. J Clin Oncol. 2012;30 Suppl: Abstr 2579.
   Web of Science ®Google Scholar
• ClinicalTrials.Gov. Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer. Available from http://clinicaltrials.gov/ct2/show/NCT01453153. ClinicalTrials.gov Identifier: NCT01453153. Accessed March 21, 2014.
   Google Scholar
• Erkan M, Reiser-Erkan C, Michalski CW, et al. Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia. 2009;11:497–508.
   PubMed Web of Science ®Google Scholar
• Masamune A, Kikuta K, Watanabe T, Satoh K, Hirota M, Shimosegawa T. Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol. 2008;295:G709–G717.
   PubMed Web of Science ®Google Scholar
• Hwang RF, Yokoi K, Bucana CD, et al. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res. 2003;9:6534–6544.
   PubMed Web of Science ®Google Scholar
• Lang SA, Taeger J, Hackl C, et al. Effects of TKI258, a novel FGFR/PDGFR/VEGFR inhibitor, on pancreatic cancer cells, endothelial cells and pericytes. Abstract 145 presented at the Gastrointestinal Cancers Symposium, San Francisco, CA, USA, January 15–17, 2009.
   Google Scholar
• ClinciaTrials.Gov. Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers. Available from http://clinicaltrials.gov/ct2/show/NCT01497392. ClinicalTrials.gov Identifier: NCT01497392. Accessed March 21, 2014.
   Google Scholar
• Palmer KR, Kerr M, Knowles G, et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg. 1994;81:882–885.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7:593–600.
   PubMed Web of Science ®Google Scholar
• Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III trial. J Clin Oncol. 2005;23:3509–3516.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Quietzsch D, Gieseler F, et al. Randomized Phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946–3952.
   PubMed Web of Science ®Google Scholar
• Colucci G, Labianca R, Di Costanzo F, et al. Randomized Phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010;28:1645–1651.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Labianca R, Hinke A, Louvet C. Increased survival using platinum analogue combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD Intergroup study and a German multicenter study. Ann Oncol. 2007;18:1652–1659.
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Schull B, Ulrich-Pur H, et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized Phase II trial. Ann Oncol. 2003;14:97–104.
   PubMed Web of Science ®Google Scholar
• Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2007;25:2607–2615.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008;8:82.
   PubMed Web of Science ®Google Scholar
• Belli C, Cereda S, Reni M. Role of taxanes in pancreatic cancer. World J Gastroenterol. 2012;7;18:4457–4465.
   Web of Science ®Google Scholar
• Okada S, Sakata Y, Matsuno S, et al. Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan. Br J Cancer. 1999;80:438–443.
   PubMed Web of Science ®Google Scholar
• Androulakis N, Kourousis C, Dimopoulos MA, et al. Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter Phase II study. J Clin Oncol. 1999;17:1779–1785.
   PubMed Web of Science ®Google Scholar
• Whitehead RP, Jacobson J, Brown TD, Taylor SA, Weiss GR, Macdonald JS. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol. 1997;15:2414–2419.
   PubMed Web of Science ®Google Scholar
• Rougier P, Adenis A, Ducreux M, et al. A Phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer. 2000;36:1016–1025.
   PubMed Web of Science ®Google Scholar
• Schneider BP, Ganjoo KN, Seitz DE, et al. Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology. 2003;65:218–223.
   PubMed Web of Science ®Google Scholar
• Sherman WH, Fine RL. Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas. Oncology. 2001;60:316–321.
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Mavroudis D, Tsavaris N, et al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a Phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol. 2001;12:101–103.
   PubMed Web of Science ®Google Scholar
• Ryan DP, Kulke MH, Fuchs CS, et al. A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer. 2002;94:97–103.
   PubMed Web of Science ®Google Scholar
• Saif MW, Podoltsev NA, Rubin MS, et al. Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer. Cancer Invest. 2010;28:186–194.
   PubMed Web of Science ®Google Scholar
• Löhr JM, Haas SL, Bechstein WO, et al. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled Phase II trial. Ann Oncol. 2012;23:1214–1222.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Exp Opin Pharmacother. 2006;7:1041–1053.
   PubMed Web of Science ®Google Scholar
• Vogel SM, Minshall RD, Pilipovic M, Tiruppathi C, Malik AB. Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein. Am J Physiol Lung Cell Mol Physiol. 2001;281:L1512–L1522.
   PubMed Web of Science ®Google Scholar
• Infante JR, Matsubayashi H, Sato N, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol. 2007;25:319–325.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a Phase I/II trial. J Clin Oncol. 2011;29:4548–4554.
   PubMed Web of Science ®Google Scholar
• Frese KK, Neesse A, Cook N, et al. Nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012;2:260–269.
   PubMed Web of Science ®Google Scholar
• ClincialTrials.Gov. Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer. Available from http://clinicaltrials.gov/ct2/show/NCT01851174. ClinicalTrials.gov Identifier: NCT01851174. Accessed March 21, 2014.
   Google Scholar
• Hosein PJ, de Lima Lopes G Jr, Pastorini VH, et al. A Phase II trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol. 2013;36:151–156.
   PubMed Web of Science ®Google Scholar
• MacKenzie S, Zeh H, McCahill LE, et al. A pilot Phase II multicenter study of nab-paclitaxel (Nab-P) and gemcitabine (G) as preoperative therapy for potentially resectable pancreatic cancer (PC). J Clin Oncol. 2013;31 Suppl:Abstr 4038.
   Google Scholar
• Alvarez R, Musteanu M, Garcia-Garcia E, et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer. 2013;109:926–933.
   PubMed Web of Science ®Google Scholar
• Kunzmann V, Hartlapp I, Scheurlen M, et al. Sequential neoadjuvant chemotherpy with nab-paclitaxel plus gemcitabine and FOLFIRINOX in locally advanced pancreatic cancer (LAPC): a PILOT study. J Clin Oncol. 2013;31 Suppl:Abstr e15193. Available from: http://meetinglibrary.asco.org/content/114422-132. Accessed March 21, 2104.
   Google Scholar
• Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest. 2001;107:1049–1054.
   PubMed Web of Science ®Google Scholar
• Arnold SA, Brekken RA. SPARC: a matricellular regulator of tumorigenesis. J Cell Commun Signal. 2009;3:255–273.
   PubMed Web of Science ®Google Scholar
• Guweidhi A, Kleeff J, Adwan H, et al. Osteonectin influences growth and invasion of pancreatic cancer cells. Ann Surg. 2005;242:224–234.
   PubMed Web of Science ®Google Scholar
• Prenzel KL, Warnecke-Eberz U, Xi H, et al. Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater. Oncol Rep. 2006;15:1397–1401.
   Web of Science ®Google Scholar
• Mantoni TS, Schendel RR, Rödel F, et al. Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. Cancer Biol Ther. 2008;7:1806–1815.
   PubMed Web of Science ®Google Scholar
• Delany AM. Matricellular proteins osteopontin and osteonectin/SPARC in pancreatic carcinoma. Cancer Biol Ther. 2010;10:65–67.
   PubMed Web of Science ®Google Scholar
• Rivera LB, Brekken RA. SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-β1 activity. J Cell Biol. 2011;193:1305–1319.
   Web of Science ®Google Scholar
• Bradshaw AD. The role of SPARC in extracellular matrix assembly. J Cell Commun Signal. 2009;3:239–246.
   PubMed Web of Science ®Google Scholar
• Watkins G, Douglas-Jones A, Bryce R, Mansel RE, Jiang WJ. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids. 2005;72:267–272.
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Giatromanolaki A, Brekken RA, et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res. 2003;63:5376–5380.
   PubMed Web of Science ®Google Scholar
• Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol. 1999;30:339–344.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–7803.
   PubMed Web of Science ®Google Scholar
• Lobo C, Lopes G, Silva O, Gluck S. Paclitaxel albumin-bound particles (Abraxane™) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute. Biomed Pharmacother. 2007;61:531–533.
   PubMed Web of Science ®Google Scholar
• Yardley DA, Daniel BR, Inhorn RC, et al. SPARC microenvironment signature (SMS) analysis of a Phase II trial of neoadjuvant gemcitabine (G), epirubicin (E), and nab-paclitaxel (nab-P) in locally advanced breast cancer (LABC). J Clin Oncol. 2010;28:741 Suppl:Abstr 10574.
   Web of Science ®Google Scholar
• Socinski MA, Manikhas GM, Stroyakovsky DL, et al. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010;5:852–861.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Bondarenko I, Karaeva N, et al. Survival results of a randomized, Phase 3 trial of nab-paclitaxel and carboplatin compared with Cremophor-based paclitaxel and carboplatin as first- line therapy in advanced non-small cell lung cancer. J Clin Oncol. 2011;29:488 Suppl:Abstr 7551.
   Google Scholar
• Hersh EM, O’Day SJ, Ribas A, et al. A Phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer. 2010;116:155–163.
   PubMed Web of Science ®Google Scholar
• Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P, Gradishar WJ. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs. 2008;19:899–909.
   PubMed Web of Science ®Google Scholar
• Shao H, Tang H, Salavaggione OE, et al. Improved response to nab-paclitaxel compared with Cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer. J Thorac Oncol. 2011;6:998–1005.
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol. 2009;2:59–64.
   PubMed Web of Science ®Google Scholar
• Neesse A, Frese KK, Chan DS, et al. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut. September 25, 2013. [Epub ahead of print.]
   Web of Science ®Google Scholar
• ClinicalTrials.Gov. A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT02005315. ClinicalTrials.gov Identifier: NCT02005315. Accessed March 21, 2014.
   Google Scholar
• ClinicalTrials.Gov. Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma. Available from: http://clinicaltrials.gov/ct2/show/NCT01431794. ClinicalTrials.gov Identifier: NCT01431794. Accessed March 21, 2014.
   Google Scholar
• ClinicalTrials.Gov. Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas. Available from: http://clinicaltrials.gov/ct2/show/NCT01088815. ClinicalTrials.gov Identifier: NCT01088815. Accessed March 21, 2014.
   Google Scholar
• ClinicalTrials.Gov. PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01839487. ClinicalTrials.gov Identifier: NCT01839487. Accessed March 21, 2014.
   Google Scholar
• ClinicalTrials./Gov. Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors. Available from: http://clinicaltrials.gov/ct2/show/NCT01804530. ClinicalTrials.gov Identifier: NCT01804530. Accessed March 21, 2014.
   Google Scholar
• ClinicalTrials.Gov. A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01647828. ClinicalTrials.Gov identifier: NCT01647828. Accessed March 21, 2104.
   Google Scholar
• ClinicalTrials.Gov. Efficacy & Safety of ODSH (2-0, 3–0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane. Available from: http://clinicaltrials.gov/ct2/show/NCT01461915. ClinicalTrials.gov Identifier: NCT01461915. Accessed March 21, 2014.
   Google Scholar
• ClinicalTrials.Gov. M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01621243. ClinicalTrials.gov Identifier: NCT01621243. Accessed March 21, 2014.
   Google Scholar
• ClinicalTrials.Gov. Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01844817. ClinicalTrials.gov Identifier: NCT01844817. Accessed March 21, 2014.
   Google Scholar
• ClinicalTrials.Gov. Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors. Available from: http://clinicaltrials.gov/ct2/show/NCT01858883. ClinicalTrials.gov Identifier: NCT01858883. Accessed March 21, 2014.
   Google Scholar
• ClinicalTrials.Gov. Study to Compare Disease-free Survival of Subjects With Surgically Resected Pancreatic Cancer in the Adjuvant Setting Who Are Taking Nab-paclitaxel in Combination With Gemcitabine vs Gemcitabine Alone. Available from: http://clinicaltrials.gov/ct2/show/NCT01964430. ClinicalTrials.gov Identifier: NCT01964430. Accessed March 21, 2014.
   Google Scholar
• ClinicalTrials.Gov. Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine. Available from: http://clinicaltrials.gov/ct2/show/NCT01978184. ClinicalTrials.gov Identifier: NCT01978184. Accessed March 21, 2014.
   Google Scholar
• ClinicalTrials.Gov. Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma. Available from: http://clinicaltrials.gov/ct2/show/NCT01470417. ClinicalTrials.gov Identifier: NCT01470417. Accessed March 21, 2014.
   Google Scholar
• ClinicalTrials.Gov. Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer – 2. Available from: http://clinicaltrials.gov/ct2/show/NCT02024009. ClinicalTrials.gov Identifier: NCT02024009. Accessed March 21, 2014.
   Google Scholar